X
Mar 12, 2021 08:26 AM (GMT+8) · EqualOcean
Shanghai LUOQI Biomedical Technology Co., Ltd., an innovative nano antibody drug R & D enterprise, announced the completion of a round of financing of RMB 100 million. This round of financing was led by Tianhui capital, followed by Taiyu investment and Fuhui venture capital, and Haoyue capital acted as the exclusive financial consultant of this round of financing. This round of financing is mainly used to promote the ind application and clinical research of inhaled nano antibody asthma treatment drugs, as well as the development of many other follow-up pipeline projects.